BTMD on Nasdaq
biote Corp.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Glass House Brands Inc., MARIMED INC. or Cronos Group Inc, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Pellet Procedures Product Revenue brought in 71% of the revenue biote Corp. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Pellet Procedures Product Revenue | $150.3M | $137.0M |
| Dietary Supplements | $36.0M | $42.9M |
| Disposable Trocars Product Revenue | $4.3M | $4.9M |
| Other Service Revenue | $2.3M | $2.9M |
| Shipping Fees And Other Product Revenue | $1.5M | $2.1M |
| Contract-Term Services Revenue | $1.2M | $1.4M |
| Training Service Revenue | $1.5M | $1.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin53¢$101.8M
- Other costs30¢$57.4M
- Income tax3¢$6.0M
- Profit14¢$27.0M
Out of $192.2M in revenue.2
Where each dollar of operating cash went, fiscal 2025
- Capital spending14¢$5.0M
- Dividends paid5¢$1.7M
- Share buybacks10¢$3.4M
- Kept or used elsewhere71¢$25.1M
Out of $35.2M of cash from operations.2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $192.2M | $197.2M |
| Cost of revenue | $54.9M | $58.1M |
| Selling, general, and administrative | $101.8M | $107.5M |
| Income from operations | $35.6M | $31.6M |
| Interest expense, net | -$11.0M | -$11.0M |
| Gain (loss) from change in fair value of earnout liabilities | $13.0M | -$19.6M |
| Other income (expense), net | -$29.0K | $11.0K |
| Total other income (expense), net | $2.0M | -$30.6M |
| Income before provision for income taxes | $37.6M | $1.0M |
| Income tax expense | $6.0M | $970.0K |
| Net income | $31.6M | $46.0K |
| Less: Net income (loss) attributable to noncontrolling interest | $4.6M | -$3.1M |
| Net income attributable to biote Corp. stockholders | $27.0M | $3.2M |
| Foreign currency translation adjustments | $6.0K | -$15.0K |
| Other comprehensive income (loss) | $6.0K | -$15.0K |
| Comprehensive income attributable to biote Corp. stockholders | $31.6M | $31.0K |
| Basic | $0.86 | $0.09 |
| Diluted | $0.74 | $0.09 |
| Basic | 31.3M shares | 34.3M shares |
| Diluted | 36.7M shares | 34.3M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2024-08-31 |
|---|---|---|---|
| Cash and cash equivalents | $24.1M | $39.3M | |
| Accounts receivable, net | $6.9M | $7.6M | |
| Inventory, net | $19.1M | $14.8M | |
| Other current assets | $4.6M | $6.3M | |
| Total current assets | $54.7M | $68.1M | |
| Property and equipment, net | $10.8M | $7.0M | |
| Capitalized software, net | $4.5M | $3.9M | |
| Goodwill | $5.8M | $5.8M | |
| Intangible assets, net | $4.3M | $5.5M | |
| Operating lease right-of-use assets | $2.7M | $3.2M | $1.4M |
| Deferred tax assets, net | $24.8M | $28.7M | |
| Other non-current assets | $72.0K | $72.0K | |
| Total assets | $107.6M | $122.4M | |
| Accounts payable | $6.8M | $5.8M | |
| Accrued expenses | $9.8M | $11.3M | |
| Term loan, current | $6.2M | $6.2M | |
| Deferred revenue, current | $3.0M | $3.0M | |
| Earnout liabilities, current | $100.0K | ||
| Operating lease liabilities, current | $592.0K | $523.0K | $40.0K |
| Share repurchase liabilities, current | $18.5M | $24.6M | |
| Total current liabilities | $45.0M | $51.5M | |
| Term loan, net of current portion | $95.8M | $101.2M | |
| Revolving loans | $5.0M | ||
| Deferred revenue, net of current portion | $1.1M | $1.6M | |
| Operating lease liabilities, net of current portion | $2.3M | $2.9M | $1.3M |
| Share repurchase liabilities, net of current portion | $44.3M | ||
| Other non-current liability | $344.0K | $1.5M | |
| TRA liability | $4.4M | $4.5M | |
| Earnout liabilities, net of current portion | $4.1M | $17.1M | |
| Total liabilities | $158.0M | $224.6M | |
| Additional paid-in capital | $0 | $0 | |
| Accumulated deficit | -$49.5M | -$100.3M | |
| Accumulated other comprehensive loss | -$29.0K | -$35.0K | |
| Treasury stock, at cost | -$9.0M | -$5.6M | |
| biote Corp.'s stockholders' deficit | -$58.5M | -$105.9M | |
| Noncontrolling interest | $8.1M | $3.7M | |
| Total stockholders' deficit | -$50.4M | -$102.2M | |
| Total liabilities and stockholders' deficit | $107.6M | $122.4M | |
| Preferred stock, par or stated value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | $31.6M | $46.0K |
| Depreciation and amortization | $3.7M | $3.6M |
| Bad debt expense | $1.7M | $1.5M |
| Amortization of debt issuance costs | $833.0K | $819.0K |
| Provision for obsolete inventory | $2.0M | $503.0K |
| Non-cash lease expense | $545.0K | $815.0K |
| Non-cash interest on share repurchase liability | $3.2M | $2.6M |
| Share-based compensation expense | $8.9M | $8.7M |
| (Gain) loss from change in fair value of earnout liabilities | -$13.0M | $19.6M |
| Deferred income taxes | $4.0M | -$2.9M |
| Accounts receivable | -$958.0K | -$2.3M |
| Inventory | -$6.2M | $3.7M |
| Other assets | $1.7M | $2.9M |
| Accounts payable | $1.0M | $1.5M |
| Deferred revenue | -$400.0K | $190.0K |
| Accrued expenses | -$2.7M | $4.6M |
| Payments pursuant to TRA | -$93.0K | |
| Operating lease liabilities | -$523.0K | -$762.0K |
| Net cash provided by operating activities | $35.2M | $45.2M |
| Purchases of property and equipment | -$5.0M | -$6.4M |
| Purchases of capitalized software | -$1.8M | -$526.0K |
| Acquisitions, net of cash acquired | -$11.8M | |
| Net cash used in investing activities | -$6.9M | -$18.8M |
| Repurchases of Class A common stock | -$3.4M | -$5.6M |
| Borrowings on revolving loans | $5.0M | |
| Principal repayments on term loan | -$6.2M | -$6.2M |
| Payments on repurchase liability | -$37.6M | -$62.2M |
| Proceeds from exercise of stock options | $226.0K | $2.4M |
| Issuance of stock under purchase plan | $142.0K | $282.0K |
| Distributions | -$1.7M | -$4.7M |
| Net cash used in financing activities | -$43.6M | -$76.1M |
| Effect of exchange rate changes on cash and cash equivalents | $6.0K | -$22.0K |
| Net decrease in cash and cash equivalents | -$15.2M | -$49.7M |
| Cash paid for interest | $7.9M | $9.5M |
| Cash paid for income taxes | $2.8M | $2.6M |
| Capital expenditures and capitalized software included in accounts payable | $50.0K | |
| Shares issued to acquire Simpatra | $1.8M |
Former names
- Haymaker Acquisition Corp. IIIAug 6, 2020 to May 25, 20223
Recent filings
- Sep 18, 2026SCHEDULE 13G/A
- Sep 1, 2026SCHEDULE 13G/A
- Aug 28, 2026SCHEDULE 13G
- Aug 12, 20264
- Aug 7, 202610-Q
- Aug 5, 20268-K
- Jul 27, 2026SCHEDULE 13G/A
- Jun 17, 20268-K/A
- Jun 16, 20264 PRIMARY DOCUMENT
- Jun 10, 20264 PRIMARY DOCUMENT
- Jun 10, 20264 PRIMARY DOCUMENT
- Jun 2, 20268-K
- May 18, 20268-K
- May 14, 20264
- May 13, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARbiote Corp. filings on SEC EDGAR
- 2SEC EDGARbiote Corp. 10-K for fiscal 2025
- 3SEC EDGARbiote Corp. filings on SEC EDGAR
- 4SEC EDGARbiote Corp. 10-K for fiscal 2021
- 5SEC EDGARbiote Corp. 10-K for fiscal 2022
- 6SEC EDGARbiote Corp. 10-K for fiscal 2023
- 7SEC EDGARbiote Corp. 10-K for fiscal 2021
- 8SEC EDGARbiote Corp. 10-Q for fiscal 2025
- 9SEC EDGARbiote Corp. 10-Q for fiscal 2025
- 10SEC EDGARbiote Corp. 10-Q for fiscal 2026
- 11SEC EDGARbiote Corp. 10-Q for fiscal 2025